Vladana Stojiljkovic

Ms. Vladana Stojiljkovic

Biochemistry, University of Niš, Faculty of Medicine, Niš, Serbia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JBJelena Bašić
Jelena Bašić
VMVuk D. Milošević
Vuk D. Milošević
BDBranka Djordjevic
Branka Djordjevic
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
MŽMilica Dejan Živanović
Milica Dejan Živanović
ISIvana Stojanovic
Ivana Stojanovic
This study investigated the diagnostic accuracy of plasma biomarkers—specifically, matrix metalloproteinase (MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), CD147, and the MMP-/TIMP-1 ratio in patients with Alzheimer’s disease (AD) dementia. The research cohort comprised patients diagnosed with probable AD dementia and a control group of cognitively unimpaired (CU) individuals. Neuroradiological assessments included brain magnetic resonance imaging (MRI) following dementia protocols, with subsequent volumetric analysis. Additionally, cerebrospinal fluid (CSF) AD biomarkers were classified using the A/T/N system, and apolipoprotein E (APOE) ε4 carrier status was determined. Findings revealed elevated plasma levels of MMP-9 and TIMP-1 in AD dementia patients compared to CU individuals. Receiver operating characteristic (ROC) curve analysis demonstrated significant differences in the areas under the curve (AUC) for MMP-9 (p < 0.001) and TIMP-1 (p < 0.001). Notably, plasma TIMP-1 levels were significantly lower in APOE ε4+ patients than in APOE ε4− patients (p = 0.041). Furthermore, APOE ε4+ patients exhibited reduced hippocampal volume, particularly in total, right, and left hippocampal measurements. TIMP-1 levels exhibited a positive correlation, while the MMP-9/TIMP-1 ratio showed a negative correlation with hippocampal volume parameters. This study sheds light on the potential use of TIMP-1 as a diagnostic marker and its association with hippocampal changes in AD.

10 August 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
BDBoris Djindjic
Boris Djindjic
BDBranka Djordjevic
Branka Djordjevic
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
DSDijana Stojanović
Dijana Stojanović
IMIvan Matejic
Ivan Matejic
Background: Coronavirus disease 2019 (COVID‐19) profoundly affects the immune and hematopoietic systems with various degrees of reactive changes in the blood cell counts. Immuno‐inflammatory indices are considered a simple and effective tool in the prediction of COVID‐19 outcomes. We aimed to evaluate and compare the usefulness of leukocyte and platelet counts‐based immuno‐inflammatory indices on admission to hospital in predicting COVID‐19 progression and mortality.Methods: A total of 945 patients were enrolled. In addition to blood cell counts, we assessed hemogram‐derived immuno‐inflammatory indices in relation to COVID‐19 progression and death. The indices were tested by analysis of variance, receiver operating characteristic curve analysis, and binomial logistic regressions.Results: Patients with severe COVID‐19 had significantly higher counts of neutrophils, eosinophils, and large immature cells (LIC), while decreased counts of platelets and monocytes. Lymphopenia was found in all of the patients, but without significant association with the outcomes. Patients with a LIC count ≥0.265 x 09/L had 54.7% more odds of having COVID‐19 progression. In multivariable analyses, platelets/neutrophil‐to‐lymphocyte ratio (P/NLR) and platelets‐to‐neutrophil radio (P/N) were significant independent predictors of COVID‐19 progression and mortality. The odds of a poor outcome were two times higher in cases with P/NLR < 43 x 109/L and P/N < 29 x 109/L.Conclusion: Indices that include platelet count in combination with neutrophil and/or lymphocyte counts displayed the best discriminatory ability and prognostic value of COVID‐19 outcomes. Additionally, LIC showed promising results in the early identification of severe COVID‐19.

6 February 2026 in Medicina
Verified
Journal Article
Open access
PDF file
BDBranka Djordjevic
Branka Djordjevic
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
AVAleksandra Veličkov
Aleksandra Veličkov
JKJana Kocic
Jana Kocic
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
TCTatjana Cvetkovic
Tatjana Cvetkovic
Intense physical activity imposes substantial oxidative, metabolic, and immunological stress on the human body. It is often accompanied by reductions in plasma glutamine levels, making this amino acid conditionally essential. Glutamine plays a vital role in energy production, nitrogen transport, acid–base balance, antioxidant defense, and immune function. It is required in the biosynthesis of neurotransmitters, nucleotides, nicotinamide-derived coenzymes, glutathione, and hexosamines, making it a candidate for supporting exercise recovery. In addition, glutamine may support key mechanisms involved in muscle adaptation and recovery during exercise-induced stress by contributing to redox balance, energy sensing, anabolic signaling, intestinal barrier integrity, and immune function. This narrative review aims to synthesize biochemical mechanisms underlying glutamine effects relevant to exercise and evaluate preclinical and clinical findings on supplementation outcomes, with emphasis on timing strategies. Preclinical findings demonstrate that glutamine can modulate protein synthesis, reduce oxidative stress, improve intestinal integrity, and attenuate immune and inflammatory disturbances. Limited preclinical data suggest that post-exercise supplementation may better resolve muscle and organ damage. Clinical trials, however, report heterogeneous outcomes: several studies show improvements in markers of intestinal permeability and intestinal epithelial damage, oxidative stress, muscle damage, and inflammation, whereas others report minimal or no effect, including limited influence on performance outcomes. Variability in timing protocols, participant characteristics, and measured endpoints contributes to inconsistent findings. Overall, glutamine demonstrates several biologically plausible mechanisms that could support recovery and overall health in active individuals, athletes, and specific clinical populations. However, current evidence remains insufficient to determine clear supplementation benefits or define an optimal timing strategy. Future research using standardized protocols and integrated biochemical and functional endpoints is needed to clarify timing effects. Until such evidence emerges, recommendations should remain individualized, considering athlete-specific needs.

23 December 2022 in Journal of International Medical Research
Verified
Journal Article
Open access
TCTatjana Cvetkovic
Tatjana Cvetkovic
SSSandra Saric
Sandra Saric
NSNikola Stefanović
Nikola Stefanović
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
BDBranka Djordjevic
Branka Djordjevic
MIMarina Deljanin Ilic
Marina Deljanin Ilic
Objective: To define which oxidative stress markers could be used as diagnostic tools in the assessment of post-infarction heart failure (HF). Methods: This observational study enrolled patients with HF that were divided into three subgroups (ejection fraction [EF] ≥ 50%; EF 40–49%; EF < 40%) and age- and sex-matched healthy control subjects. The plasma concentrations of advanced oxidation protein products (AOPP), thiobarbituric acid reactive substances, catalase activity and free thiols were determined in all participants. Results: The study enrolled 81 patients with HF and 68 healthy control subjects. There were significant differences in the values ​​of oxidative stress markers between patients and controls. Oxidative stress parameters did not differ between the subgroups of patients, except for AOPP, which was significantly higher in the EF < 40% group. Univariate and multivariate logistic regression analyses showed an association between AOPP and HF in the EF ≥ 50% group, while receiver operating characteristic (ROC) curve analysis identified a cut-off value of 60.89 µmol/l for AOPP. Conclusions: Based on the ROC curve analysis of AOPP and the higher significance in the multivariate analyses for patients with EF ≥ 50%, these current results suggest that AOPP could be a useful additional tool in the assessment of post-infarction HF.

17 January 2024 in Facta Universitatis, Series: Medicine and Biology
Verified
Journal Article
Open access
PDF file
JBJelena Bašić
Jelena Bašić
VMVuk D. Milošević
Vuk D. Milošević
BDBranka Djordjevic
Branka Djordjevic
NSNikola Stefanović
Nikola Stefanović
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
ISIvana Stojanović
Ivana Stojanović
Single nucleotide polymorphisms (SNPs) rs429358 and rs7412, the most commonly investigated variants in the apolipoprotein E gene (APOE) are crucial for APOEε4 carrier status determination. However, their association with inflammatory cytokine levels in patients with dementia due to Alzheimer’s disease (AD) remains unclear. This study aimed to investigate the influence of the APOEε4 allele on pro-inflammatory cytokine levels in the cerebrospinal fluid of patients with AD dementia. The research was conducted on 36 patients with probable dementia due to AD. APOE rs429358 and rs7412 were analyzed using the Real-Time PCR method with allele-specific TaqMan assays, followed by the analysis of APOEε4 allele carrier status. Patients carrying at least one APOEε4 allele were assigned as APOEε4+. Core biomarkers (Aβ42/40 ratio, t-Tau, p-Tau levels), as well as pro-inflammatory cytokine (Tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b)) levels, were determined in the patient’s cerebrospinal fluid (CSF) using Enzyme-linked Immunosorbent Assay (ELISA). Seventeen patients (47.22%) were assigned as APOEε4+. CSF TNF-α levels were significantly higher in APOEε4+ AD dementia patients in comparison to APOEε4- patients (p<0.001), while no significant differences in IL-1b levels between these two groups were obtained. Correlation analysis showed that TNF-α negatively correlated with the Aβ42/40 ratio (p=0.033), while positive correlation with t-Tau and p-Tau was observed (p=0.001, p=0.015, respectively). These findings highlight the potential significance of TNF-α in the context of APOEε4 positivity and its implications in AD pathology.

1 December 2022 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
NSNikola Stefanović
Nikola Stefanović
MVMarija Đ. Vukelić-Nikolić
Marija Đ. Vukelić-Nikolić
BDBranka Djordjevic
Branka Djordjevic
JBJelena Bašić
Jelena Bašić
TCTatjana Cvetković
Tatjana Cvetković
Standard biomarkers for the diagnosis and follow-up of chronic kidney disease patients are appropriate neither in early diagnostics, adequate follow-up and progression assessment nor in complication development risk assessment. For that reason, a search for new, more suitable biomarkers continues. Various studies suggested microRNAs as a potential solution, as they are involved in the pathogenesis of diabetic nephropathy, kidney cancer and kidney function impairment in general. Internet search engines were used to find and select relevant literature data and electronic databases. Research published so far, in oncology especially, have reported various single microRNAs and panels of microRNAs as candidates for routine diagnostic implementation. Chronic kidney disease is, however, quite complex in terms of etiology of the disease occurrence, since there are many causes that can lead to kidney tissue damage and impairment of its function and finally full development of the chronic kidney disease. MicroRNAs are stable in bodily fluids, and hemodialysis procedure does not affect their levels. Also, high RNase activity in chronic kidney disease patients does not accelerate microRNA degradation in their samples. Literature data suggest that microRNAs are appropriate candidates for diagnostic use in chronic kidney disease. However, there are challenges that are yet to be overcome in order to use microRNAs routinely.